Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Published byDewi Hadiman Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window."— Presentation transcript:

1 Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting.
Maraba treatment results in complete responses in the window of opportunity setting. (A) Schematic representation of the treatment schedule used for the tumor rechallenge model. (B to D) Tumor growth and Kaplan-Meier survival curves obtained using 4T1 (B), EMT6 (C), or E0771 (D) cells in the tumor rechallenge model (n = 10 mice per group per experiment). Maraba treatments were administered intratumorally. NT, no treatment. (E and F) The same experiment as in (B) was repeated using intravenous delivery of Maraba virus (E) or immunocompromised CD-1 nude mice (F). (G) Primary EMT6 or 4T1 tumors were treated with Maraba or left untreated and were resected, and all animals were rechallenged with 4T1 tumors. The dotted lines indicate the time of Maraba treatment. Statistical analysis for tumor measurements: *P < 0.05, **P < 0.01, ***P < (unpaired multiple two-tailed t test). Statistical analysis for survival curves: *P < 0.05, **P < 0.01, ***P < (Mantel-Cox test). Marie-Claude Bourgeois-Daigneault et al., Sci Transl Med 2018;10:eaao1641 Published by AAAS

Download ppt "Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window."

Similar presentations

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.
Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.

Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.
Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.

Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.
Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.
Fig. 5 Maraba induces antitumor T cell immunity.

Fig. 5 Maraba induces antitumor T cell immunity.
Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to.

Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to.
In vivo prophylactic and therapeutic efficacy of C12G6 in mice

In vivo prophylactic and therapeutic efficacy of C12G6 in mice
Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.
In vivo responses of AMLMLL to ATRi.

In vivo responses of AMLMLL to ATRi.
Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.
Fig. 8. In vivo suppression of MM by CMLD

Fig. 8. In vivo suppression of MM by CMLD
Molecular Therapy - Oncolytics

Molecular Therapy - Oncolytics
Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.
Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.
Fig. 1 DMF promotes viral infection.

Fig. 1 DMF promotes viral infection.
Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade

Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade
CAR8 failure in an OT1 TCR transgenic T cell after exposure to OVA

CAR8 failure in an OT1 TCR transgenic T cell after exposure to OVA
Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.
Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 5 A competent Fc is required for the antitumor immune response.
Fig. 5. Vascularization of human liver seed grafts.

Fig. 5. Vascularization of human liver seed grafts.

Similar presentations

Ads by Google